Drug Trial Radar · NCT00057811
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Last checked: Nov 20, 2026Latest source record: Sep 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Jun 2004
Primary completion
Oct 2009
Study completion Jul 2014
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 9, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 29 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.
Conditions
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- Stage I Childhood Large Cell Lymphoma
- Stage I Childhood Small Noncleaved Cell Lymphoma
- Stage II Childhood Large Cell Lymphoma
- Stage II Childhood Small Noncleaved Cell Lymphoma
- Stage III Childhood Large Cell Lymphoma
- Stage III Childhood Small Noncleaved Cell Lymphoma
- Stage IV Childhood Large Cell Lymphoma
- Stage IV Childhood Small Noncleaved Cell Lymphoma
- Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
doxorubicin hydrochlorideDrug
Given IV, IT, or orally
cyclophosphamideDrug
Given IV
methotrexateDrug
Given IV or IT
rasburicaseDrug
Given IV
leucovorin calciumDrug
Given IV or orally
prednisoneDrug
Given IV or orally
methylprednisoloneDrug
Given IV or orally
filgrastimBiological
Given subcutaneously
rituximabBiological
Given IV
cytarabineDrug
Given IT
etoposideDrug
Given IV
vincristine sulfateDrug
Given IV
hydrocortisone sodium succinateDrug
Given IT
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grade ≥ 3 StomatitisTime frame: Up to 1 year
- Response RateTime frame: Up to 5 years
- Minimal Residual DiseaseTime frame: Not Provided
- Toxic DeathTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Oncology Group
Arcadia, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.